Paramount Merger Pause, Meta AI Optimism, and the Peptide Boom

What It Covers

Kara Swisher and Scott Galloway analyze three major stories: the Paramount-Skydance merger pause triggered by Democratic AGs seeking delay rather than legal victory, Meta's tone-deaf AI optimism ad campaign, and the FDA's consideration of loosening restrictions on peptides amid influencer-driven demand and minimal clinical evidence.

Key Questions Answered

• •Merger Arbitrage Signal: Paramount shares hit a 52-week low and trade at $25 versus the deal's $31 per share price — a roughly 22% discount — indicating markets assign approximately a one-in-four chance the deal closes. Investors reading merger arbitrage spreads provides a faster, more reliable signal of deal viability than following legal arguments or management spin calling court delays "significant wins."
• •Oracle Stock as Deal Tracker: The Paramount-Skydance merger's fate is directly tied to Oracle's stock price, which is down 52% year-over-year and 39% year-to-date. Since Oracle shares effectively track OpenAI's prospects, monitoring OpenAI's narrative and valuation over the next six months provides the clearest leading indicator of whether the Ellison family retains financial staying power to see the deal through.
• •Delay as Litigation Strategy: Democratic AGs filing against the Paramount merger do not need to win at trial — they need only delay closing long enough to make the deal economically untenable. A $650 million quarterly ticking fee begins in October, meaning prolonged litigation could exceed the deal's value. Recognizing delay-as-strategy reframes how to evaluate antitrust challenges against politically approved mergers.
• •Brand Repair Requires Restraint, Not Ads: Meta's AI optimism campaign invites scrutiny by claiming human connection while simultaneously cutting 10% of its workforce and facing documented teen mental health harms. The actionable lesson for companies with reputational damage: avoid aspirational advertising that contradicts known behavior. Instead, execute quiet, verifiable programs — Meta's $150 million vocational training investment is cited as the correct approach.
• •Peptide Gray Market Risk: Peptides sourced through compounding pharmacies and telehealth platforms outside FDA approval frequently originate from Chinese manufacturers with no quality controls. Unlike GLP-1s, which carry FDA approval and accumulating real-world safety data, most trending peptides lack conclusive clinical studies. Anyone considering peptide use should require medical supervision, regular bloodwork, and verified domestic sourcing before starting any protocol.
• •Legacy Media's Competitive Blind Spot: A combined Paramount and Warner Brothers would represent roughly 12% of total US TV watch time, while YouTube holds 13% and Netflix leads overall. Fighting a merger battle costing hundreds of millions per quarter while YouTube, Netflix, and AI-generated content scale freely accelerates competitive disadvantage. Legacy media companies should treat regulatory battles as opportunity costs measured against the scaling velocity of digital competitors.